Goldman Sachs Maintains Sell on Harmony Biosciences, Lowers Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has maintained a 'Sell' rating on Harmony Biosciences (NASDAQ:HRMY) and lowered the price target from $40 to $31.
September 26, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained a 'Sell' rating on Harmony Biosciences and lowered the price target from $40 to $31.
The 'Sell' rating maintained by Goldman Sachs and the lowering of the price target from $40 to $31 indicates a negative outlook for Harmony Biosciences. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100